ID   SMS-LHN
AC   CVCL_9539
DR   Cosmic; 717429
DR   Cosmic; 848931
DR   IARC_TP53; 23821
DR   Wikidata; Q54954993
RX   DOI=10.1007/0-306-46872-7_2;
RX   PubMed=7037175;
RX   PubMed=8242562;
RX   PubMed=11507071;
RX   PubMed=15720811;
RX   PubMed=15892104;
RX   PubMed=24792489;
WW   Provider; CCR; -; https://www.cccells.org/dl/NB_Data_Sheets/SMS-LHN_Cell_Line_Data_Sheet_COGcell_org.pdf
CC   Characteristics: Neuroblastic type (N-type) (PubMed=15720811).
CC   Doubling time: 216 hours (COG).
CC   Omics: Variations; Array-based CGH.
ST   Source(s): COG
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 9,13
ST   D16S539: 8,9
ST   D18S51: 16,19
ST   D19S433: 15
ST   D21S11: 27,28
ST   D2S1338: 17,19
ST   D3S1358: 16,18
ST   D5S818: 10,11
ST   D7S820: 8,11
ST   D8S1179: 13,14
ST   FGA: 19,23
ST   TH01: 9.3,10
ST   TPOX: 8,9
ST   vWA: 15,18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   2Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 16
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999).
//
RX   PubMed=7037175;
RA   Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.;
RT   "Selective toxicity of 6-hydroxydopamine and ascorbate for human
RT   neuroblastoma in vitro: a model for clearing marrow prior to
RT   autologous transplant.";
RL   Cancer Res. 42:1331-1336(1982).
//
RX   PubMed=8242562; DOI=10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E;
RA   Wada R.K., Seeger R.C., Brodeur G.M., Einhorn P.A., Rayner S.A.,
RA   Tomayko M.M., Reynolds C.P.;
RT   "Human neuroblastoma cell lines that express N-myc without gene
RT   amplification.";
RL   Cancer 72:3346-3354(1993).
//
RX   PubMed=11507071;
RA   Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,
RA   Gomer C.J., Triche T.J., Reynolds C.P.;
RT   "Loss of p53 function confers high-level multidrug resistance in
RT   neuroblastoma cell lines.";
RL   Cancer Res. 61:6185-6193(2001).
//
RX   PubMed=15720811; DOI=10.1593/neo.04310; PMCID=PMC1531688;
RA   Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F.,
RA   Biedler J.L., Cheung N.-K.V., Ross R.A.;
RT   "Characteristics of stem cells from human neuroblastoma cell lines and
RT   in tumors.";
RL   Neoplasia 6:838-845(2004).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K.A., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//